Navigation
banner

Antiviral Drugs Research & Development

2017-09-192017-06-132017-05-13
Register 3 for the price of 2 with the coupon code rcdvb!


registration button

Subscribe for updates




Dear Colleague,

Innovative approaches in the development of antiviral drugs is crucial for improvements of current therapies and possible new indications. Continually emerging global viral threats along with antiviral resistance and viral immune evasion pose a significant challenge to current antivirals. Increased awareness and understanding in these areas aid our progress towards better treatment regimens.

Leaders in industry and academia will discuss current landscape and emerging new therapies in the field of HIV, RSV, Hepatitis B/C, Influenza etc. New drug designs and their mechanism of actions, approaches to address immune evasion mechanisms and viral resistance, and challenges in clinical study designs will also be discussed. We invite you to attend and engage with other prominent thinkers in the field on July 13-14, 2017 in Baltimore, MD.

Session Topics:

  1. Plenary Session: Responding to Emerging Infectious Diseases on the Global Stage
  2. Respiratory Viral Infections: Current Landscape and Emerging Drugs
  3. Blood Borne Pathogens: New Frontiers in Research and Drug Development
  4. Challenges in Clinical Study Design and Considerations
  5. Panel: New Approaches to Antiviral Development
  6. General Session: Public/Private Partnerships in Support of Global Health

We hope to see you there!

 

Best regards,

The 2017 Advisory Committee

 

2017 Program Director
Rupa Challa, Spring Bank Pharmaceuticals
2017 Advisory Board Members
Tara Strutt, University of Central Florida
Nafija Serdarevic, University of Sarajevo
Kris Iyer, Spring Bank Pharmaceuticals
Kai Mckinstry, University of Central Florida
Kevin Gilligan, ClinicalRM
Seshadri Vasan, Public Health England & University of York
Priscilla Yang, Harvard Medical School
Nicholas Meanwell, Bristol-Myers Squibb